Synonyms: BMS-986016 | BMS986016 | ONO-4482 | Opdualag® (nivolumab + relatlimab-rmbw) | relatlimab-rmbw
relatlimab is an approved drug (EMA & FDA (2022))
Compound class:
Antibody
Comment: Relatlimab (BMS-986016) is an anti-LAG3 monoclonal antibody that was developed for utility in cancer immunotherapy.
|
References |
1. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI et al.. (2004)
Role of LAG-3 in regulatory T cells. Immunity, 21 (4): 503-13. [PMID:15485628] |
2. Lonberg N, Srinivasan M. (2014)
Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof. Patent number: WO2014008218. Assignee: Bristol-Myers Squibb Company. Priority date: 02/07/2012. Publication date: 09/01/2014. |
3. Nguyen LT, Ohashi PS. (2015)
Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol, 15 (1): 45-56. [PMID:25534622] |
4.
Fully human monoclonal antibody specific for lymphocyte activation gene 3 and nivolumab.
Accessed on 21/09/2017. Modified on 21/09/2017. fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=595017 |